Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12178.158 | 0.2933 | -0.6205 | 0.7379 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12178.158 | 0.2741 | -0.6539 | 0.7379 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12178.158 | 0.2370 | -0.7157 | 0.7379 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12178.158 | 0.0794 | -0.9355 | 0.7379 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12178.158 | 0.0106 | -0.9958 | 0.7379 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12291.165 | 0.9028 | 0.6662 | 0.5602 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12291.165 | 0.8086 | 0.3688 | 0.5602 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12291.165 | 0.7933 | 0.3227 | 0.5602 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12291.165 | 0.4393 | -0.5394 | 0.5602 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12291.165 | 0.2100 | -0.8767 | 0.5602 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12291.165 | 0.2063 | -0.8805 | 0.5602 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12291.165 | 0.1654 | -0.9195 | 0.5602 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12291.165 | 0.0347 | -0.9951 | 0.5602 | |
| BT-474 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12291.165 | 0.0079 | -0.9997 | 0.5602 | |
| BT-483 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 11855.158 | 0.9148 | 0.7592 | 0.6941 | |
| BT-483 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 11855.158 | 0.8814 | 0.6674 | 0.6941 | |
| BT-483 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 11855.158 | 0.8970 | 0.7102 | 0.6941 | |
| BT-483 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 11855.158 | 0.8970 | 0.7102 | 0.6941 | |
| BT-483 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 11855.158 | 0.8403 | 0.5566 | 0.6941 | |
| BT-483 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 11855.158 | 0.8920 | 0.6963 | 0.6941 | |
| BT-483 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 11855.158 | 0.7506 | 0.3230 | 0.6941 | |
| BT-483 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 11855.158 | 0.4160 | -0.4347 | 0.6941 | |
| BT-483 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 11855.158 | 0.0113 | -0.9969 | 0.6941 | |
| BT-549 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12305.165 | 0.8857 | 0.9121 | 2.7020 | |
| BT-549 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12305.165 | 0.8971 | 0.9212 | 2.7020 |